All NewsNews & Politicsnews

Novartis bets up to $900M for radioligand therapy from China’s BoomRay

Wednesday, September 23, 2026Tristan ManalacView original

Novartis is the current radiopharma leader with two FDA-approved therapies in Pluvicto and Lutathera.

Read the full article on the original site.